Zacks Investment Research cut shares of HUTCHISON CHINA/S (NASDAQ:HCM) from a hold rating to a sell rating in a report released on Wednesday.
According to Zacks, “Hutchison China MediTech Limited researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. The Company offers drugs for oncology and autoimmune diseases treatment. Hutchison China MediTech Limited is based in Hong Kong. “
Separately, BidaskClub lowered HUTCHISON CHINA/S from a buy rating to a hold rating in a research note on Thursday, August 23rd.
NASDAQ:HCM opened at $31.62 on Wednesday. HUTCHISON CHINA/S has a 12 month low of $25.76 and a 12 month high of $42.25. The company has a quick ratio of 4.55, a current ratio of 4.67 and a debt-to-equity ratio of 0.06. The company has a market cap of $4.16 billion, a price-to-earnings ratio of -143.73 and a beta of 0.01.
Large investors have recently bought and sold shares of the business. Royal Bank of Canada purchased a new stake in shares of HUTCHISON CHINA/S in the first quarter valued at approximately $199,000. Renaissance Technologies LLC grew its position in shares of HUTCHISON CHINA/S by 375.0% in the third quarter. Renaissance Technologies LLC now owns 32,300 shares of the company’s stock valued at $1,040,000 after purchasing an additional 25,500 shares in the last quarter. Millennium Management LLC purchased a new stake in shares of HUTCHISON CHINA/S in the first quarter valued at approximately $1,009,000. State of New Jersey Common Pension Fund D purchased a new stake in shares of HUTCHISON CHINA/S in the second quarter valued at approximately $2,651,000. Finally, Sumitomo Mitsui Trust Holdings Inc. grew its position in shares of HUTCHISON CHINA/S by 12.3% in the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 121,430 shares of the company’s stock valued at $3,660,000 after purchasing an additional 13,345 shares in the last quarter. Institutional investors own 11.79% of the company’s stock.
About HUTCHISON CHINA/S
Hutchison China MediTech Limited, a biopharmaceutical company, engages in the research, development, manufacture, and sale of pharmaceuticals and healthcare products primarily in the People's Republic of China and Hong Kong. It operates through Innovation Platform and Commercial Platform segments.
Further Reading: Google Finance Portfolio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for HUTCHISON CHINA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHISON CHINA/S and related companies with MarketBeat.com's FREE daily email newsletter.